Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 376
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Mark Barrett | Chief Business Officer | 無 | 無 | 無 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
截至 2024年5月1日 止,Madrigal Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中:4;董事會:9;股東權利:8;現金賠償:7。